<strong>Background:</strong> This work evaluated the capacity of a dry emulsion as a carrier of viable microorganisms with potential use as prophylaxis of infectious diseases. <strong>Methods:</st...<strong>Background:</strong> This work evaluated the capacity of a dry emulsion as a carrier of viable microorganisms with potential use as prophylaxis of infectious diseases. <strong>Methods:</strong> The aqueous phase containing <em>P. multocida </em>not viable in PBS was emulsified in mineral oil to obtain a w/o emulsion. The microorganisms remained stable and only in two cases (n = 6) did the bacterial concentration decrease. Scanning Electron Microscopy (SEM) revealed a structure of a system with the organized association of particles with cubic symmetry. Using two <em>ex vivo </em>bioadhesion systems, it was demonstrated that the disperse-adsorbed system is capable of adhering to the intestinal mucosa and remains adhered for long periods of time. <strong>Results: </strong>The no viability of the bacteria in the dry emulsion and the possibility of controlled release were confirmed. <em>In vivo </em>trial was conducted in pigs. It was possible to locate the emulsion and the bacteria attached to the gut of the living animal. An ELISA kit was used to monitor the mean antibody titer of treated pigs over a 2-week period, and a classic primary response curve occurred when the titer was plotted against time. <strong>Conclusion: </strong>We propose the disperse-adsorbed system as an alternative to commonly used vehicles for immunogens in the oral vaccines.展开更多
目的:研究榄香烯口服乳联合甲磺酸阿帕替尼治疗晚期胃癌的疗效性及安全性,探讨适合晚期胃癌三线治疗的方案。方法:选取南通大学附属如皋医院2020年1月—2021年6月二线化疗失败的晚期胃癌患者50例,按随机数字表法分为观察组和对照组,各2...目的:研究榄香烯口服乳联合甲磺酸阿帕替尼治疗晚期胃癌的疗效性及安全性,探讨适合晚期胃癌三线治疗的方案。方法:选取南通大学附属如皋医院2020年1月—2021年6月二线化疗失败的晚期胃癌患者50例,按随机数字表法分为观察组和对照组,各25例。对照组予单药甲磺酸阿帕替尼500 mg/d口服,8周为1个疗程,同时予最佳支持治疗。观察组在对照组的基础上予榄香烯口服乳饭前空腹口服,20 mL/次,tid,6周为1个疗程,停用2周后重复下1个疗程。比较两组患者临床疗效、客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、无进展生存时间(progression-free-survival,PFS)、生存质量(quality of life,QOL)及不良反应发生情况。结果:观察组的ORR、DCR优于对照组,但差异无统计学意义(P>0.05);观察组中位PFS、QOL改善情况优于对照组(P<0.05);两组的不良反应发生比较差异无统计学意义(P>0.05)。结论:榄香烯口服乳联合甲磺酸阿帕替尼能提高晚期胃癌的临床疗效,且耐受性好,不良反应轻微,具有一定的临床价值。展开更多
文摘<strong>Background:</strong> This work evaluated the capacity of a dry emulsion as a carrier of viable microorganisms with potential use as prophylaxis of infectious diseases. <strong>Methods:</strong> The aqueous phase containing <em>P. multocida </em>not viable in PBS was emulsified in mineral oil to obtain a w/o emulsion. The microorganisms remained stable and only in two cases (n = 6) did the bacterial concentration decrease. Scanning Electron Microscopy (SEM) revealed a structure of a system with the organized association of particles with cubic symmetry. Using two <em>ex vivo </em>bioadhesion systems, it was demonstrated that the disperse-adsorbed system is capable of adhering to the intestinal mucosa and remains adhered for long periods of time. <strong>Results: </strong>The no viability of the bacteria in the dry emulsion and the possibility of controlled release were confirmed. <em>In vivo </em>trial was conducted in pigs. It was possible to locate the emulsion and the bacteria attached to the gut of the living animal. An ELISA kit was used to monitor the mean antibody titer of treated pigs over a 2-week period, and a classic primary response curve occurred when the titer was plotted against time. <strong>Conclusion: </strong>We propose the disperse-adsorbed system as an alternative to commonly used vehicles for immunogens in the oral vaccines.
文摘目的:研究榄香烯口服乳联合甲磺酸阿帕替尼治疗晚期胃癌的疗效性及安全性,探讨适合晚期胃癌三线治疗的方案。方法:选取南通大学附属如皋医院2020年1月—2021年6月二线化疗失败的晚期胃癌患者50例,按随机数字表法分为观察组和对照组,各25例。对照组予单药甲磺酸阿帕替尼500 mg/d口服,8周为1个疗程,同时予最佳支持治疗。观察组在对照组的基础上予榄香烯口服乳饭前空腹口服,20 mL/次,tid,6周为1个疗程,停用2周后重复下1个疗程。比较两组患者临床疗效、客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、无进展生存时间(progression-free-survival,PFS)、生存质量(quality of life,QOL)及不良反应发生情况。结果:观察组的ORR、DCR优于对照组,但差异无统计学意义(P>0.05);观察组中位PFS、QOL改善情况优于对照组(P<0.05);两组的不良反应发生比较差异无统计学意义(P>0.05)。结论:榄香烯口服乳联合甲磺酸阿帕替尼能提高晚期胃癌的临床疗效,且耐受性好,不良反应轻微,具有一定的临床价值。
